Innovative Healthcare Institute shared on LinkedIn:
“First-line treatment selection in sensitizing EGFR-mutated NSCLC requires careful evaluation of efficacy, toxicity, administration, patient characteristics, and preferences.
At the Best of Lung Cancer Conference, Mohammad Kashif Riaz, MD of St. Elizabeth Healthcare and Jennifer Leddo, MD of the University of Cincinnati will participate in a focused debate exploring two approaches:
- Osimertinib-based treatment
- Lazertinib-amivantamab treatment
Join us for a balanced, clinically relevant discussion designed to illuminate the considerations behind treatment selection.”
October 3, 2026 | Cincinnati, Ohio